Cargando…

Pharmacogenetics of taxane‐induced neurotoxicity in breast cancer: Systematic review and meta‐analysis

Taxane‐based chemotherapy regimens are used as first‐line treatment for breast cancer. Neurotoxicity, mainly taxane‐induced peripheral neuropathy (TIPN), remains the most important dose‐limiting adverse event. Multiple genes may be associated with TIPN; however, the strength and direction of the ass...

Descripción completa

Detalles Bibliográficos
Autores principales: Guijosa, Alberto, Freyria, Ana, Espinosa‐Fernandez, Jose Rodrigo, Estrada‐Mena, Francisco J., Armenta‐Quiroga, Ana Sofía, Ortega‐Treviño, Maria Fernanda, Catalán, Rodrigo, Antonio‐Aguirre, Bani, Villarreal‐Garza, Cynthia, Perez‐Ortiz, Andric C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9579387/
https://www.ncbi.nlm.nih.gov/pubmed/35892315
http://dx.doi.org/10.1111/cts.13370
_version_ 1784812170147528704
author Guijosa, Alberto
Freyria, Ana
Espinosa‐Fernandez, Jose Rodrigo
Estrada‐Mena, Francisco J.
Armenta‐Quiroga, Ana Sofía
Ortega‐Treviño, Maria Fernanda
Catalán, Rodrigo
Antonio‐Aguirre, Bani
Villarreal‐Garza, Cynthia
Perez‐Ortiz, Andric C.
author_facet Guijosa, Alberto
Freyria, Ana
Espinosa‐Fernandez, Jose Rodrigo
Estrada‐Mena, Francisco J.
Armenta‐Quiroga, Ana Sofía
Ortega‐Treviño, Maria Fernanda
Catalán, Rodrigo
Antonio‐Aguirre, Bani
Villarreal‐Garza, Cynthia
Perez‐Ortiz, Andric C.
author_sort Guijosa, Alberto
collection PubMed
description Taxane‐based chemotherapy regimens are used as first‐line treatment for breast cancer. Neurotoxicity, mainly taxane‐induced peripheral neuropathy (TIPN), remains the most important dose‐limiting adverse event. Multiple genes may be associated with TIPN; however, the strength and direction of the association remain unclear. For this reason, we systematically reviewed observational studies of TIPN pharmacogenetic markers in breast cancer treatment. We conducted a systematic search of terms alluding to breast cancer, genetic markers, taxanes, and neurotoxicity in Ovid, ProQuest, PubMed, Scopus, Virtual Health, and Web of Science. We assessed the quality of evidence and bias profile. We extracted relevant variables and effect measures. Whenever possible, we performed random‐effects gene meta‐analyses and examined interstudy heterogeneity with meta‐regression models and subgroup analyses. This study follows the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) and STrengthening the REporting of Genetic Association Studies (STREGA) reporting guidance. A total of 42 studies with 19,431 participants were included. These evaluated 262 single‐nucleotide polymorphisms (SNPs) across 121 genes. We conducted meta‐analyses on 23 genes with 60 SNPs (19 studies and 6246 participants). Thirteen individual SNPs (ABCB1‐rs2032582, ABCB1‐rs3213619, BCL6/‐rs1903216, /CAND1‐rs17781082, CYP1B1‐rs1056836, CYP2C8‐rs10509681, CYP2C8‐rs11572080, EPHA5‐rs7349683, EPHA6‐rs301927, FZD3‐rs7001034, GSTP1‐rs1138272, TUBB2A‐rs9501929, and XKR4‐rs4737264) and the overall SNPs' effect in four genes (CYP3A4, EphA5, GSTP1, and SLCO1B1) were statistically significantly associated with TIPN through meta‐analysis. In conclusion, through systematic review and meta‐analysis, we found that polymorphisms, and particularly 13 SNPs, are associated with TIPN, suggesting that genetics does play a role in interindividual predisposition. Further studies could potentially use these findings to develop individual risk profiles and guide decision making.
format Online
Article
Text
id pubmed-9579387
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-95793872022-10-19 Pharmacogenetics of taxane‐induced neurotoxicity in breast cancer: Systematic review and meta‐analysis Guijosa, Alberto Freyria, Ana Espinosa‐Fernandez, Jose Rodrigo Estrada‐Mena, Francisco J. Armenta‐Quiroga, Ana Sofía Ortega‐Treviño, Maria Fernanda Catalán, Rodrigo Antonio‐Aguirre, Bani Villarreal‐Garza, Cynthia Perez‐Ortiz, Andric C. Clin Transl Sci Research Taxane‐based chemotherapy regimens are used as first‐line treatment for breast cancer. Neurotoxicity, mainly taxane‐induced peripheral neuropathy (TIPN), remains the most important dose‐limiting adverse event. Multiple genes may be associated with TIPN; however, the strength and direction of the association remain unclear. For this reason, we systematically reviewed observational studies of TIPN pharmacogenetic markers in breast cancer treatment. We conducted a systematic search of terms alluding to breast cancer, genetic markers, taxanes, and neurotoxicity in Ovid, ProQuest, PubMed, Scopus, Virtual Health, and Web of Science. We assessed the quality of evidence and bias profile. We extracted relevant variables and effect measures. Whenever possible, we performed random‐effects gene meta‐analyses and examined interstudy heterogeneity with meta‐regression models and subgroup analyses. This study follows the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) and STrengthening the REporting of Genetic Association Studies (STREGA) reporting guidance. A total of 42 studies with 19,431 participants were included. These evaluated 262 single‐nucleotide polymorphisms (SNPs) across 121 genes. We conducted meta‐analyses on 23 genes with 60 SNPs (19 studies and 6246 participants). Thirteen individual SNPs (ABCB1‐rs2032582, ABCB1‐rs3213619, BCL6/‐rs1903216, /CAND1‐rs17781082, CYP1B1‐rs1056836, CYP2C8‐rs10509681, CYP2C8‐rs11572080, EPHA5‐rs7349683, EPHA6‐rs301927, FZD3‐rs7001034, GSTP1‐rs1138272, TUBB2A‐rs9501929, and XKR4‐rs4737264) and the overall SNPs' effect in four genes (CYP3A4, EphA5, GSTP1, and SLCO1B1) were statistically significantly associated with TIPN through meta‐analysis. In conclusion, through systematic review and meta‐analysis, we found that polymorphisms, and particularly 13 SNPs, are associated with TIPN, suggesting that genetics does play a role in interindividual predisposition. Further studies could potentially use these findings to develop individual risk profiles and guide decision making. John Wiley and Sons Inc. 2022-08-17 2022-10 /pmc/articles/PMC9579387/ /pubmed/35892315 http://dx.doi.org/10.1111/cts.13370 Text en © 2022 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Research
Guijosa, Alberto
Freyria, Ana
Espinosa‐Fernandez, Jose Rodrigo
Estrada‐Mena, Francisco J.
Armenta‐Quiroga, Ana Sofía
Ortega‐Treviño, Maria Fernanda
Catalán, Rodrigo
Antonio‐Aguirre, Bani
Villarreal‐Garza, Cynthia
Perez‐Ortiz, Andric C.
Pharmacogenetics of taxane‐induced neurotoxicity in breast cancer: Systematic review and meta‐analysis
title Pharmacogenetics of taxane‐induced neurotoxicity in breast cancer: Systematic review and meta‐analysis
title_full Pharmacogenetics of taxane‐induced neurotoxicity in breast cancer: Systematic review and meta‐analysis
title_fullStr Pharmacogenetics of taxane‐induced neurotoxicity in breast cancer: Systematic review and meta‐analysis
title_full_unstemmed Pharmacogenetics of taxane‐induced neurotoxicity in breast cancer: Systematic review and meta‐analysis
title_short Pharmacogenetics of taxane‐induced neurotoxicity in breast cancer: Systematic review and meta‐analysis
title_sort pharmacogenetics of taxane‐induced neurotoxicity in breast cancer: systematic review and meta‐analysis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9579387/
https://www.ncbi.nlm.nih.gov/pubmed/35892315
http://dx.doi.org/10.1111/cts.13370
work_keys_str_mv AT guijosaalberto pharmacogeneticsoftaxaneinducedneurotoxicityinbreastcancersystematicreviewandmetaanalysis
AT freyriaana pharmacogeneticsoftaxaneinducedneurotoxicityinbreastcancersystematicreviewandmetaanalysis
AT espinosafernandezjoserodrigo pharmacogeneticsoftaxaneinducedneurotoxicityinbreastcancersystematicreviewandmetaanalysis
AT estradamenafranciscoj pharmacogeneticsoftaxaneinducedneurotoxicityinbreastcancersystematicreviewandmetaanalysis
AT armentaquirogaanasofia pharmacogeneticsoftaxaneinducedneurotoxicityinbreastcancersystematicreviewandmetaanalysis
AT ortegatrevinomariafernanda pharmacogeneticsoftaxaneinducedneurotoxicityinbreastcancersystematicreviewandmetaanalysis
AT catalanrodrigo pharmacogeneticsoftaxaneinducedneurotoxicityinbreastcancersystematicreviewandmetaanalysis
AT antonioaguirrebani pharmacogeneticsoftaxaneinducedneurotoxicityinbreastcancersystematicreviewandmetaanalysis
AT villarrealgarzacynthia pharmacogeneticsoftaxaneinducedneurotoxicityinbreastcancersystematicreviewandmetaanalysis
AT perezortizandricc pharmacogeneticsoftaxaneinducedneurotoxicityinbreastcancersystematicreviewandmetaanalysis